EMAIL US AT info@bcan.org
SUPPORT HOTLINE 888-901-2226
Donate Now

BCG Shortage 2019

Bacille Calmette-Guérin (BCG) has been a standard of care for many patients with non-muscle invasive bladder cancer for decades. BCAN and our Scientific Advisory Board have been advised by Merck & Co., Inc., that they anticipate a limited supply of BCG in the next year. Due to increasing global demand for BCG treatment and as the only source of TICE BCG in many countries, Merck anticipates this shortage to continue throughout 2019. Merck increased production of TICE BCG by more than 100 percent to enable it to be produced at the full extent of their manufacturing capacity. However, even with increased production, an increasing global demand is leading to supply constraints. BCAN is deeply concerned about the current BCG shortage for treatments for bladder patients. For more information about BCG and other intravesical therapies, please visit our  Intravesical Therapy page.

2/20/2019

BCAN organized a meeting of physicians and representatives of medical urological societies to help provide guidance to doctors and patients during this BCG shortage. BCAN, along with the American Urological Association, American Association of Clinical Urologists, Society of Urologic Oncology, Large Urology Group Practice Association and the Urology Care Foundation, has released a joint statement regarding suggested strategies to help maximize the care of patients with non-muscle invasive bladder cancer. As always, it is important that these decisions be made after an informed discussion with the individual patient regarding their treatment options in the context of the ongoing BCG shortage. To read the guidance, please click here. If you have any questions about this guidance, please contact BCAN.

If you want to consider enrolling in a clinical trial as an appropriate alternative management strategy to BCG treatment alone, you can find more information on BCAN’s Clinical Trial dashboard.

BCAN Special Update – BCG Shortage: Understanding your Treatment Options Webinar

To view the recording of this program featuring Dr. Seth Lerner, Dr. Robert Svatak, and patient advocate Rick Bangs, please click here.

.

BCAN Board of Directors member, Dr. Neal Shore discusses the current 2019 shortage of BCG with Dr. Ashish Kamat and Dr. Jonathan Rubenstein on video by Uro Today. Click here to learn more.

National shortages of BCG in recent years leading some clinics and hospitals to run out, and some to ration supplies. SWOG Cancer Research Network research may help us fill the void. The same clinical trials group that helped establish the effectiveness of BCG may also help establish the effectiveness of a replacement.

Read more here.

To read the full statement, please click below.

Click on the image below to read the full statement.

Click below to open the newsletter in a new tab.

Click on the image below to read the full statement.

Click on the image below to read the full article.

Frequently Asked Questions about BCG